The conversation discusses whether finasteride would still be necessary if Verteporfin becomes a successful hair loss treatment. It also explores the sensitivity of transplanted hair to DHT and the potential for off-label use of Verteporfin post hair transplant.
The post discusses concerns about the practicality of using Minoxidil foam for hair loss, including the frequency of application, preparation, coverage area, and drying time. Responsessuggest that missing a dose isn't detrimental, it can be applied once a day, it works on all hair areas, and it doesn't need to be perfectly dry before application.
The user shared their 6-month progressusing Dutasteride .5 daily, RU 100mg once a day, and 15 mg oral Minoxidil for hair loss. They reported visible results, no side effects, and increased body hair, despite concerns from others about the high dosage and potential health risks.
The user "Curious_Conflict_959" shared a progress picture of their hair transplant after 5 months. They used a low dosage of RU on native hairs and had PRP treatments. All hair loss hasstopped.
Dutasteride is often preferred over Finasteride due to fewer side effects and better hair regrowth. Initial side effects like lowered libido may occur but typically diminish over time.
The conclusion of the conversation is that the user has experienced significant hair regrowth using a combination of medications, including dutasteride, RU58841, and minoxidil. They have not experienced any noticeable side effects and are considering a hair transplant in the future.
A 36-year-old considering a fourth hair transplant is advised to either shave his head or use a hair system due to poor results from previous transplants and late medication use. He plans to consult top surgeons and adjust his current treatments, including finasteride and minoxidil.
Minoxidil, often combined with microneedling, has helped some users improve hair growth at the temples and hairline. Finasteride is also mentioned as a treatment, with mixed results on its effectiveness.
The post and conversation discuss Verteporfin's potential as a hair loss treatment. It'sshown promise in regrowing hair after transplants and might be effective with microneedling.
RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.
The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.
Minoxidil alone is often insufficient for treating hair loss because it doesn't address the DHT-related cause. Combining it with finasteride, a DHT blocker, is generally more effective.
A 19-year-old experienced worsening hair loss after 4 months on finasteride, despite initial improvement with minoxidil. The consensus is to continue treatment for at least a year, asshedding is common and often temporary.
A user shared their successful hair regrowth using a combination of derma stamping, Retinol, Minoxidil, Dutasteride, and RU58841, with no side effects. Others discussed their varied experiences with these treatments, including concerns about potential side effects like heart issues and sexual dysfunction.
Comparing two upcoming topical hair loss treatments, Fluridil and Breezula, to determine which is most effective for treating hair loss, taking into consideration factorssuch as price, side effects, potential for hair growth, convenience of application, smell, greasiness, and styling after use.
Stopping finasteride often restoressexual function, with many experiencing improved libido and erections. Some usersswitch to minoxidil or topical finasteride to manage side effects while maintaining hair health.
There have been no new effective hair loss treatmentssince finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.
The conclusion of the conversation is that dying the hair can be an effective method for managing hair loss, particularly for those with diffuse thinning.
User switched from finasteride and minoxidil to dutasteride, experienced side effects, then took dutasteride once a week with improved hair density. Another user had success with daily dutasteride, while one had no results from topical dutasteride.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it isseen as progress in hair loss treatment.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Eucapil's effectiveness is questioned due to unconvincing clinical trial and lack of FDA approval.
A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.
The conversation discusses whether RU58841, if FDA approved and safe, would be recommended over finasteride for hair loss. Specific treatments mentioned include RU58841, finasteride, and minoxidil.
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.
The conversation discusses a user's experience with hair loss treatments, specifically using finasteride for almost 5 months and minoxidil for 8 months. The user is considering switching to oral minoxidil and possibly dutasteride if not satisfied with the results, despite others noting progress and advising patience.